Glutathione depletion in human erythrocytes and rat liver: a study on the interplay between bioactivation and inactivation functions of liver and blood

Citation for published version (APA):

Palmen, N. G. M., & Evelo, C. T. A. (1996). Glutathione depletion in human erythrocytes and rat liver: a study on the interplay between bioactivation and inactivation functions of liver and blood. *Toxicology in Vitro*, 10, 273-281. [https://doi.org/10.1016/0887-2333\(96\)00002-1](https://doi.org/10.1016/0887-2333(96)00002-1)

Document status and date:

Published: 01/01/1996

DOI:

[10.1016/0887-2333\(96\)00002-1](https://doi.org/10.1016/0887-2333(96)00002-1)

Document Version:

Publisher's PDF, also known as Version of record

Document license:

Taverne

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

Download date: 26 Apr. 2023

Glutathione Depletion in Human Erythrocytes and Rat Liver: a Study on the Interplay Between Bioactivation and Inactivation Functions of Liver and Blood

N. G. M. PALMEN† and C. T. A. EVELO*

Department of Pharmacology, Toxicology Section, University of Limburg, PO Box 616, 6200 MD Maastricht, The Netherlands

(Accepted 17 October 1995)

Abstract—The interplay between bioactivation and inactivation functions of human erythrocytes and rat liver was studied. Glutathione depletion was used as a measure of the amount of reduced glutathione (GSH)-reactive compound. Iodoacetamide (IAcA), *N*-ethylmaleimide (NEM) and diethyl maleate (DEM), which are electrophiles that need no metabolic activation, were able to deplete GSH in incubations with either aqueous GSH solution or erythrocytes. These results indicate that these compounds can pass the erythrocyte membrane. Cyclophosphamide (CP), 3-hydroxyacetanilide (3-HAA) and 2-methylfurane (2-MF) needed metabolic activation by rat liver microsomes to deplete glutathione in incubations with aqueous GSH solution or erythrocytes. By measuring the sum of both reduced and oxidized glutathione [= total glutathione (GT)] it became clear that GSH-reactive metabolites are generated out of CP, 3-HAA and 2-MF by the action of microsomes and that these metabolites can pass through the erythrocyte membrane. As GT depletion was higher when microsomes of phenobarbital-pretreated rats were used, the metabolites were (are expected to be) generated by phenobarbital-inducible enzymes. GT was also depleted in incubations with haemolysate and 3-HAA or 2-MF but not in incubations with aqueous GSH solution, which indicates that erythrocyte cytosol can metabolize 3-HAA and 2-MF into GSH-reactive compounds. The pesticides monuron and monolinuron did not affect GT concentrations when aqueous GSH solution, haemolysate or erythrocytes with or without microsomal activating system were tested. When hepatocytes were incubated with 3-HAA or CP (2 mM), about 2 mM of internal GT concentration was depleted. The hepatocytes excreted GSH-reactive metabolites generated from 3-HAA and CP (about 20% of the metabolites formed for 3-HAA). Erythrocyte GT was not depleted in co-incubations of hepatocytes and erythrocytes with 3-HAA. This can be explained by the amounts of GSH-reactive metabolites excreted by the hepatocytes, which would require very effective uptake by the erythrocytes in order to be detectable. Copyright © 1996 Elsevier Science Ltd

INTRODUCTION

Glutathione in its reduced form (GSH) and glutathione *S*-transferase (GST) have key roles in the detoxification of electrophilic compounds (DeLeve and Kaplowitz, 1991; Mannervik and Danielson, 1988; Meister and Anderson, 1983). Human erythrocytes contain a high concentration of GSH (about 2 mM) (Fazi *et al.*, 1991) and a relatively high GST activity (1–6 U haemoglobin/g towards the common

substrate 1-chloro-2,4-dinitrobenzene) (Evelo and Henderson, 1992; Strange *et al.*, 1982). Erythrocytes may therefore act as circulating bioreactors, conjugating electrophiles near or in the tissues where they originate. This may lead to consumption of erythrocyte GSH, and, in fact, various electrophiles are known to cause glutathione depletion in human erythrocytes *in vitro* (Calabrese *et al.*, 1988; Evelo and Henderson, 1988; Fazi *et al.*, 1991) and *in vivo* (Evelo and Henderson, 1992; Mulders, 1995).

Erythrocytes also contain mixed-function oxidase (MFO) activity capable of generating GSH-reactive compounds, an activity that according to Belvedere and Tursi (1981) must be attributed to oxyhaemoglobin. Erythrocytes are, for instance, known to metabolize styrene into styrene oxide (Belvedere and Tursi, 1981; Norppa *et al.*, 1983; Tursi *et al.*, 1983), benzo[*a*]pyrene into quinones (Lo Jacono *et al.*, 1992) and heterocyclic amines into intermediates with mutagenic activity (Duverger-van Bogaert *et al.*, 1991), to hydroxylate aniline (Mieyal *et al.*, 1976),

*Author for correspondence.

†Current address: Arbodienst Limburg, Maastricht, The Netherlands.

Abbreviations: CP = cyclophosphamide; DEM = diethyl maleate; GSH = reduced glutathione; GST = glutathione *S*-transferase; GT = total glutathione; 3-HAA = 3-hydroxyacetanilide; IAcA = iodoacetamide; LDH = lactate dehydrogenase; MAS = microsomal activating system; 2-MF = 2-methylfurane; MFO = mixed-function oxidase; MLN = monolinuron; NEM = *N*-ethylmaleimide; PB = phenobarbital; PBS = phosphate buffered saline; TCA = trichloroacetic acid.

and to perform oxidative demethylation on methyl-aniline with concomitant release of formaldehyde (Stecca and Duverger-van Bogact, 1989).

For most compounds, the activity of electrophilic metabolite formation is much higher in the liver than in erythrocytes (Guengerich and Liebler, 1985). Although liver-generated electrophilic metabolites may be detoxified within the hepatocytes, they can also be excreted, enter the erythrocytes in the sinusoids and deplete erythrocyte glutathione.

In the present investigation, attention was paid to the interplay between the bioactivation and inactivation functions of liver and blood. The main questions, approached *in vitro*, were as follows:

1. What is the importance of the bioactivating and inactivating potency of red blood cells in comparison with the hepatic capacity?
2. Are erythrocytes accessible for GSH-reactive electrophilic compounds?
3. Is the outer cell membrane of hepatocytes a barrier to reactive metabolites formed intracellularly, or is an effective detoxification occurring intrahepatically?

We developed an incubation system using different combinations of human erythrocytes, haemolysate and aqueous GSH solution with rat liver microsomes or intact hepatocytes to mimic the *in vivo* situation. The choice of two different species for target cells (human erythrocytes) and metabolizing

cells (rat hepatocytes) was made to obtain an optimal combination of significance (human target, no substances with known qualitative differences in metabolism across species used) and feasibility (rodent liver, no large volumes of rodent blood). The test systems can easily be adapted to use human liver-derived activating systems, or blood of larger animals that may sometimes be more readily available.

An outline of the various experimental conditions studied in the present investigation is shown in Fig. 1. Direct reactivity of the substrate (X) with GSH was tested in incubations with aqueous GSH solutions (arrow 1, Fig. 1). Metabolic activity of erythrocytes for the test substrates (MFO plus GST) was tested through comparison of incubations with aqueous GSH solution and incubations with haemolysate (arrow 2). The influence of erythrocyte integrity on uptake and metabolism of the test compounds was tested by comparison of incubations with haemolysate and erythrocytes (arrow 3). This influence may consist of effects of the membrane on uptake and, for example, of differences in reductive capacity due to higher oxygen exposure of the haemolysates.

Biotransformation of the test compound by means of a microsomal activating system (MAS) into glutathione-reactive metabolites was tested through incubations with aqueous GSH solution with (arrow 1') and without MAS (arrow 1). These incubations were compared with incubations in which erythrocytes and MAS were combined (arrow 3').

Biotransformation of the test compound by hepatocytes (both phase I and phase II activity) was assessed by determination of glutathione depletion. The ability of GSH-reactive metabolites to pass the hepatocyte membrane was also tested. Therefore, after incubation of substrate with hepatocytes, the intact cells were removed by centrifugation and the supernatant was incubated again with GSH (arrow 1'). Co-incubations of hepatocytes and erythrocytes (arrow 3') were used to test whether metabolites generated and excreted by hepatocytes are able to enter the erythrocyte and deplete erythrocyte glutathione.

Fig. 1. An outline of the incubations performed in this study. GSH-reactive compounds (X) can react with GSH in aqueous solution or in haemolysates; if they are able to enter the erythrocyte they can also have this effect in this cell type. Non GSH-reactive compounds can sometimes be metabolized into reactive compounds (X'). This can occur either in the erythrocyte itself, provided that the parent compound can enter the cell (if this is not the case effects may be seen only in haemolysates), or by added metabolic systems such as MAS or hepatocytes. The diagram is further explained in the text.

MATERIALS AND METHODS

Chemicals

Reduced glutathione (GSH), glucose-6-phosphate dehydrogenase (G6PDH; EC 1.1.1.49), glutathione reductase (EC 1.6.4.2), β -glucuronidase/arylsulfatase (EC 3.2.1.31/EC 3.1.6.1), glucose-6-phosphate (G6P), NADP(H), NADH, cyclophosphamide (CP; CAS no. 6055-19-2) and 3-hydroxyacetanilide (3-HAA; CAS no. 621-42-1) were obtained from Sigma (St Louis, MO, USA). Diethyl maleate (DEM), *N*-ethylmaleimide (NEM) and iodoacetamide (IAcA) were from Janssen Chimica (Beerse, Belgium). 2-Methylfurane (2-MF; CAS no. 534-22-5) was from Merck (Darmstadt, Germany), and monuron (MN;

CAS no. 150-68-5) and monolinuron (MLN; CAS no. 1746-81-2) were from Riedel-de Haën (Seelse, Germany). Collagenase B (from *Clostridium histolyticum*) was obtained from Boehringer (Mannheim, Germany). Water was demineralized and micro-filtered before use. All other chemicals were of analytical grade.

Animals

Male Brown Norway rats (BN/M) of about 250 g were used. Housing was as previously described (Palmen and Evelo, 1993). For phenobarbital pre-treatment the animals received 1 g/litre of the substance in their drinking water for 1 wk prior to the preparation of microsomes (PB microsomes).

Biological preparations

The preparation of the microsomal activating system was as described previously (Palmen and Evelo, 1993). The procedure for the isolation of hepatocytes was based on the methods described by Berry and Friend (1969) and by Seglen (1973). Viability of the cells (more than 90%) was determined with the trypan blue exclusion test (Jauregui *et al.*, 1981). All incubations using hepatocytes (both with and without erythrocytes) were performed in Krebs–Henseleit buffer of pH 7.4. Erythrocytes and haemolysates were prepared as previously described (Palmen and Evelo, 1993).

Incubations

The chemicals tested can be divided into direct GSH-reactive compounds (IAcA, NEM, DEM) and compounds that need further metabolization into GSH-reactive metabolites (CP, 3-HAA, 2-MF) (Garle and Fry, 1989). Two pesticides (MN and MLN) were also tested because their metabolite (4-chloroaniline) is known to generate haemoglobin adducts (Sabbioni and Neumann, 1990). As the glutathione sulfhydryl group is more sensitive to alkylation than the haemoglobin sulfhydryl group (Evelo and Henderson, 1988), MN and MLN might also affect glutathione concentrations.

Direct GSH-reactive compounds. Whole blood (1.5 ml) or an equal volume of aqueous GSH solution in phosphate buffered saline (PBS, pH 7.3), were incubated in a shaking water-bath (37°C, 210 rpm) with 50 µl of the test compounds IAcA, DEM and NEM. Final concentrations were 0, 0.5, 1.0 or 2 mM. IAcA and NEM were dissolved in PBS, and DEM in 100% ethanol. Addition of ethanol alone had no effect on the GSH values. The remaining GSH concentrations were determined after an incubation period of 1 hr for GSH solutions (initial concentration 500 µM) and of 15 min for human blood (initial GSH concentrations 860, 820 and 720 µM, for IAcA, DEM and NEM, respectively). All these experiments were performed in triplicate (1 × 3).

Other compounds. 2 ml aqueous GSH solution,

haemolysate or erythrocytes (final Hb concentrations 57 and 23 g/litre respectively) in 100 mM Na₂HPO₄/KH₂PO₄ buffer (pH 7.4) were incubated at 37°C in a shaking water-bath (80 rpm). After 5 min of preincubation, 1 ml of the test compound (CP, 3-HAA, 2-MF, MN or MLN) was added. Final concentrations were between 0 and 2 mM. Aqueous GSH and erythrocyte incubations were also performed in the presence of normal and PB-pretreated MAS, which was added before preincubation to a final protein concentration of 1 mg/ml. After 1 hr of incubation the samples were treated as previously described (Palmen and Evelo, 1993) and total glutathione (GT: the total of reduced plus oxidized glutathione) concentrations were measured. Initial GT concentrations were 440 ± 5 µM (mean ± SE) for aqueous GSH solutions (300 ± 5 µM for 2-MF), 235 ± 20 µM for haemolysates and 110 ± 4 µM for erythrocytes. All experiments were performed three times and in triplicate (3 × 3). For CP and 3-HAA, separate experiments were performed for test compound concentrations between 0 and 0.5 mM and between 0.5 and 2.0 mM.

Incubations with hepatocytes: Hepatocytes (4.4 × 10⁶ cells/ml) plus 3-HAA or CP solutions (final concentrations between 0 and 2.0 mM) were incubated in Krebs–Henseleit buffer (pH 7.4) for 1 hr (incubation volume 1.5 ml, 37°C) in a shaking water-bath (80 rpm). After the incubation period, 200 µl trichloroacetic acid (TCA) (8%) was added to an equal volume of hepatocyte suspension and GT was determined. The rest of the sample was centrifuged (5 min, 25 g) and 1 ml supernatant plus 200 µl GSH solution (final concentration between 100 and 400 µM) was incubated again under the same conditions. In order to liberate possible conjugated metabolites, β-glucuronidase/arylsulfatase was added (final activity of 650 U/ml, with the pH adjusted to 6.2 by addition of 175 µl 3 M KH₂PO₄). DEM pre-treatment was performed by incubation of 4.4 × 10⁶ cells/ml with 1 mM DEM in Krebs–Henseleit buffer for 15 min in a shaking water-bath at 37°C. Excess DEM was removed by washing twice with the same buffer.

Co-incubations of erythrocytes and hepatocytes: Co-incubations of erythrocytes and hepatocytes were performed in transwells™ (Costar, Cambridge, UK), that are composed of a well in which a smaller well (transwell) can be placed containing a porous membrane (0.4 µm). Erythrocytes (2.6 ml, Hb concentration 27 g/litre) were pipetted into the well, and the hepatocytes (1 ml, 6.6 × 10⁶ cells/ml) plus 3-HAA (0.5 ml, final concentration between 0 and 5 mM) were added to the transwell. After an incubation period of 1 hr, the erythrocytes were pipetted into plastic vials and packed by centrifugation. Further treatment was as previously described (Palmen and Evelo, 1993) and GT concentrations were determined. These

experiments were performed three times in triplicate (3×3).

Analytical procedures

GSH was determined as previously described (Evelo and Henderson, 1988). GT in the TCA supernatants was determined after dilution (nine-fold) with buffer by the cyclic oxidation reduction method described by Anderson (1985). Lactate dehydrogenase (LDH) activity was determined using NADH consumption during pyruvate transformation to lactate (Moss *et al.*, 1986). Microsomal and hepatocyte protein contents were determined according to Lowry *et al.* (1951). Haemoglobin concentrations were determined by measuring cyanmethaemoglobin according to van Kampen and Zijlstra (1965).

Statistical analysis

GT depletion caused by CP, 3-HAA, 2-MF, MN and MLN was analysed separately for both incubations with normal and PB microsomes by linear regression, using a model including control value and concentration as explanatory variables. Using that model we tested, for each metabolizing system, whether slopes of GT depletion versus concentration were significant.

RESULTS

Incubations without addition of metabolic activating system

Depletion of GSH by IAcA, NEM and DEM and depletion of GT by CP, 3-HAA and 2-MF in incubations without MAS, is shown in Figs 2, 3 and 4 for aqueous GSH solutions, erythrocytes and haemolysates, respectively.

GSH in aqueous solution was depleted by the direct GSH-reactive compounds IAcA, NEM and DEM. The most reactive compound was NEM, which brought about almost complete depletion at

Fig. 2. GSH depletions in aqueous solution after incubation with the reactive compounds IAcA (□), NEM (○) and DEM (△) (single experiments in triplicate: 1×3) and GT depletion in incubations with CP (▲), 3-HAA (▼) and 2-MF (●) (three experiments in triplicate: 3×3).

Fig. 3. GSH depletion in erythrocytes after incubation with IAcA (□), NEM (○) and DEM (△) (single experiments in triplicate: 1×3) and GT depletion in incubations with CP (▲), 3-HAA (▼) and 2-MF (●) (three experiments in triplicate: 3×3).

0.5 mM; for IAcA a comparable effect was reached at 1.0 mM. DEM was the least reactive compound. These three compounds also caused GSH depletion in erythrocytes, indicating that they do pass through erythrocyte membrane. Here, IAcA was the most effective compound, as 97% of the initial GSH concentration was depleted at a IAcA concentration of 2 mM, followed by NEM (82%) and DEM (45%).

Consistent with the fact that CP, 3-HAA, 2-MF, MN and MLN need metabolic activation, GT was not depleted in incubations of these compounds with aqueous GSH solution or erythrocytes. In incubations of haemolysates, concentration-dependent GT depletion ($P \leq 0.01$) was found for 3-HAA (depletion of $18 \mu\text{mol}/\text{mmol}$ 3-HAA) and 2-MF ($12 \mu\text{mol}/\text{mmol}$).

Incubations with MAS

In incubations with aqueous GSH solution and normal microsomes (Fig. 5), GT was depleted in a

Fig. 4. GT depletion in haemolysates by CP (▲), 3-HAA (▼) and 2-MF (●). Mean and interexperimental SE are shown for three experiments performed in triplicate (3×3). The GT depletion was concentration dependent for 3-HAA and 2-MF: asterisks indicate significant differences from control ($*P \leq 0.01$ in both cases; linear regression).

Fig. 5. GT depletion in incubations (3×3) of aqueous GSH solution and microsomes of untreated rats with CP (▲), 3-HAA (▼) and 2-MF (●). The mean and the inter-experimental SE are shown. The GT depletion was concentration dependent for all three compounds: asterisks indicate significant differences from control ($**P \leq 0.001$ in all cases; linear regression).

Fig. 7. GT depletion in incubations (3×3) of erythrocytes and microsomes of untreated rats with CP (▲), 3-HAA (▼) and 2-MF (●). The mean and interexperimental SE are shown. In some cases the SE falls within the datapoints. The GT depletion was concentration dependent for all three compounds: asterisks indicate significant differences from control ($**P \leq 0.001$; linear regression).

concentration-dependent way by CP (GT depletion was $48 \mu\text{mol}/\text{mmol}$), 3-HAA ($36 \mu\text{mol}/\text{mmol}$) and 2-MF ($25 \mu\text{mol}/\text{mmol}$) ($P \leq 0.001$ in all three cases), and not by MN or MLN. When PB microsomes were used (Fig. 6) even higher depletions were found for CP ($92 \mu\text{mol}/\text{mmol}$), 2-MF ($41 \mu\text{mol}/\text{mmol}$) and 3-HAA. For the latter compound a plateau in GT depletion was found at 3-HAA concentrations above 0.3 mM where the initial GSH concentration was about 25% depleted. For these microsomes, also, MN and MLN had no effect.

The same profile was found for erythrocytes. In the presence of normal microsomes (Fig. 7), GT was depleted in a concentration-dependent way by CP ($46 \mu\text{mol}/\text{mmol}$ CP), 3-HAA ($11 \mu\text{mol}/\text{mmol}$) and 2-MF ($23 \mu\text{mol}/\text{mmol}$) ($P \leq 0.001$ in all cases). In the

presence of PB microsomes (Fig. 8), even more marked depletion was found for CP (leading to full depletion at 0.5 mM CP), 3-HAA (depletion of $30 \mu\text{mol}/\text{mmol}$ 3-HAA) and 2-MF ($39 \mu\text{mol}/\text{mmol}$). Again MN and MLN had no effect, irrespective of the kind of microsomes used.

All effects of microsomes reported above were clearly dependent on the presence of an NADPH-regenerating system.

Incubations with hepatocytes

Viability of hepatocytes. The viability of hepatocytes after incubation was tested by measurement of LDH leakage into the medium (Jauregui *et al.*, 1981). LDH leakage was low during the first 50 min of the incubation period and increased thereafter (data not

Fig. 6. GT depletion in incubations (3×3) of aqueous GSH solution and microsomes of PB-pretreated rats with CP (▲), 3-HAA (▼) and 2-MF (●). The mean and the inter-experimental SE are shown. In some cases the SE falls within the datapoints. The GT depletion was concentration dependent for all three compounds: asterisks indicate significant differences from control ($*P \leq 0.01$ for 3-HAA; $**P < 0.001$ for CP and 2-MF; linear regression).

Fig. 8. GT depletion in incubations (3×3) of erythrocytes and microsomes of PB-pretreated rats with CP (▲), 3-HAA (▼) and 2-MF (●). The mean and interexperimental SE are shown. The GT depletion was concentration dependent for all three compounds: asterisks indicate significant differences from control ($*P \leq 0.01$ for 3-HAA and 2-MF; $**P \leq 0.001$ for CP; linear regression).

Table 1. Glutathione depletion and excretion of GSH-reactive compounds from hepatocytes incubated with 3-HAA and CP

Compound	Concentration (mM)	GT depletion ($\mu\text{mol/g}$ protein)	Excretion (μM)
3-HAA	1.0	6.0 ± 1.7 (n = 3)	0.6 (n = 1)
	2.0	9.5 ± 1.4 (n = 5)	10.4 (n = 2: 6.7, 14)
CP	1.0	15.1 (n = 1)	n.d.
	2.0	15.0 (n = 2: 10.2, 19.8)	6 (n = 1)

n.d. = not done

All values were determined after 1 hr incubation of hepatocytes with 3-HAA or CP. Where applicable, the mean $\pm$ standard error of the depletion/g protein (4 g/litre in the incubations) is given for the number of experiments shown; each experiment consisted of incubations in triplicate. Excretion of GSH reactive products was determined by reincubation (1 hr, 37°C) with GSH.

shown). The LDH leakage after 1 hr of incubation was not increased by addition of 3-HAA or CP at concentrations up to 2 mM. Incubation of hepatocytes with DEM (final concentration 1 mM, 15 min, 37°C) depleted $75 \pm 5\%$ of the initial GT concentration but had no effect on the LDH leakage.

Incubations of hepatocytes alone. The effects of 3-HAA and CP on hepatocyte GT and the excretion of GSH-reactive compounds are shown in Table 1. A concentration-dependent hepatocyte GT depletion was found for 3-HAA ($P \leq 0.01$). At 2 mM 3-HAA, this depletion amounted to about $10 \mu\text{mol/g}$ protein. In two experiments with CP, comparable or somewhat higher depletions (10 and $20 \mu\text{mol/g}$ protein at 2 mM) were found.

The ability of GSH-reactive metabolites to pass the hepatocyte membrane was tested. After completion of the incubation with test compound, hepatocytes were removed by centrifugation and the supernatants were reincubated with GSH for 1 hr under the same conditions. Table 1 shows that the GT concentration in the supernatants decreased as a result of the earlier incubation of hepatocytes with the test compound, indicating that GSH-reactive 3-HAA and CP metabolites were excreted by the hepatocytes. In one experiment part of the hepatocytes were pretreated with DEM, leading to $75 \pm 5\%$ GT depletion in the hepatocytes. After this pretreatment the excretion of GSH-reactive 3-HAA metabolites increased from 0.6 to $6.6 \mu\text{M}$ at 1 mM 3-HAA and from 6.7 to $17.8 \mu\text{M}$ at 2 mM 3-HAA. Electrophiles generated by hepatocytes may also be detoxified by conjugation to compounds other than GSH and excreted into the medium. Rashed *et al.* (1990) showed that 80% of 3-HAA metabolites formed in mice are sulfated or glucuronidated. We tried to liberate GSH-reactive compounds from such metabolites by adding β -glucuronidase/arylsulfatase to the medium of the second (GSH containing) incubation. However, addition of the esterases did not increase the GT depletion.

Co-incubations of erythrocytes and hepatocytes. Erythrocyte GT concentration was not affected when erythrocytes and hepatocytes were co-incubated. Addition of 3-HAA to these incubations (final concentrations up to 5 mM) did not affect erythrocyte GT, neither when normal hepatocytes were used nor

when hepatocytes from PB-pretreated rats were tested. In an attempt to increase the amount of GSH-reactive 3-HAA metabolites, the hepatocytes were pretreated with DEM. Although this led to 72% depletion in the hepatocytes, it did not affect the erythrocyte GT concentration. Similarly, isolation and incubation of 3-HAA-treated hepatocytes in sulfate-free medium—known to affect sulfation capacity (Evelo *et al.*, 1984)—had no effect on erythrocyte GT in co-incubations.

DISCUSSION

Most cell types are more or less able to (de)toxify foreign chemicals. The hepatocyte is known to be a metabolically very active cell and erythrocytes have some metabolic activity also (Belvedere and Tursi, 1981). Foreign compounds, toxified by hepatocytes by means of cytochrome *P*-450 activity, may be detoxified by phase II metabolism (e.g. glucuronidation, sulfation, glutathione conjugation). This may lead to a shortage of hepatocyte phase II conjugation factors such as UDP-glucuronic acid, 3'-phosphoadenosine-5'-phosphosulfate and GSH. Conjugated and/or unconjugated metabolites may be released by the hepatocyte into the sinusoids; this means that erythrocytes can be exposed to these metabolites. When the metabolites are able to pass through the erythrocyte membrane, the biochemical functions of the erythrocyte may be affected.

In the present investigation, we developed a set of *in vitro* test systems (Fig. 1) that may help to shed light on the interplay between the bioactivation and inactivation functions of liver and blood, using glutathione depletion as the dependent variable. A comparable method was described by Tingle and Park (1993), who noted methaemoglobin formation in human erythrocytes incubated with dapson in the presence of rat liver microsomes. To approach the *in vivo* situation more closely, we tested whether hepatocytes are able to generate GSH-reactive metabolites from CP or 3-HAA, and the ability of 3-HAA metabolites to deplete erythrocyte GT. As a large variety of variables (besides glutathione depletion) can be tested, the test systems may extend the current set of techniques. GSH is an efficient scavenger of reactive electrophilic substances, especially

in combination with glutathione *S*-transferases (DeLeve and Kaplowitz, 1991; Mannervik and Danielson, 1988; Meister and Anderson, 1983). Because of this property, a decrease of the GSH concentration (glutathione depletion), caused by the test compound, has been used as a measure of the amount of GSH-reactive compounds in the incubate (Garle and Fry, 1989 and 1990; Garle *et al.*, 1988).

IACa, NEM and DEM are direct GSH-reactive compounds that need no metabolic activation (Evelo and Henderson, 1988). In incubations with aqueous GSH solution and in incubations with erythrocytes, GSH was, indeed, depleted. The depletion of GSH in solutions without biological material not only confirms that these compounds need no metabolic activation but also shows that the reactions are not dependent on GST. The depletion in erythrocytes proves that the compounds are able to pass through the erythrocyte membrane. CP, 3-HAA, 2-MF, MN and MLN did not influence GT concentrations (GT is the sum of both reduced and oxidized glutathione) of aqueous GSH solutions or erythrocytes when no external metabolizing system was added, indicating that these compounds have no direct reactivity with GSH.

Both 3-HAA and 2-MF depleted GT in haemolysate but not in incubations with aqueous GSH solution or erythrocytes. The results indicate that a factor in the haemolysate is capable of metabolizing 3-HAA and 2-MF, resulting in GSH conjugation. This metabolic activity cannot be explained by mere GST-catalysed glutathione conjugation to the parent compounds, as the addition of glutathione *S*-transferase π (3.2 U/ml) to the incubations with aqueous GSH solution and 3-HAA or 2-MF, had no effect on the GT concentration (data not shown).

Only when rat MAS was added to incubations of CP, 3-HAA or 2-MF and aqueous GSH solution or erythrocytes, was GT depleted. GT depletions were concentration dependent when normal or PB microsomes were used. The presence of NADPH was a requirement. This indicates that metabolites of CP, 3-HAA and 2-MF are generated by MAS and that these metabolites are able to enter the erythrocyte. For all three compounds tested, GT depletions were higher in incubations with aqueous GSH solution than in erythrocytes when normal microsomes were tested. This may indicate that the erythrocyte membrane acts as a barrier for metabolites of CP, 3-HAA and 2-MF, generated by microsomes. If the erythrocyte membrane would limit diffusion to less than 80 nmol/hr/m² membrane, GT depletion would be less than 10% during the assay period and therefore probably would not be detectable. [The incubated amount of erythrocytes corresponds to 200 μ l cells, containing 300 nmol GSH. The amount of GSH-reactive metabolite needed to deplete 10% of this GSH pool would be 30 nmol. The membrane surface of 200 μ l erythrocytes is 0.36 m² (Guyton, 1986)].

MAS-dependent depletions by CP, 3-HAA and 2-MF were inducible by PB.

Despite the fact that MN and MLN are known to give rise to (4-chloroanilin) Hb adducts in rats (Sabbioni and Neumann, 1990), and were therefore expected to have some activity towards GSH after metabolization, we did not find any such effect.

Hepatocyte GT decreased by about 10 μ mol/g protein in incubations with 2 mM 3-HAA, and by at least this amount with 2 mM CP. Since the protein concentration of hepatocytes is about 200 g/litre, this corresponds to a GT depletion in the hepatocytes of about 2 mM. To verify whether substantial fractions of the metabolites formed were excreted by the hepatocytes, the supernatants of the 3-HAA or CP hepatocyte incubations were reincubated with GSH during 1 hr under the same conditions. The GT depletion in the supernatant of incubations with 3-HAA (2 mM) was of the order of 10 μ M. Since the mean GT depletion in the hepatocytes corresponded to 45 nmol/ml incubate, this means that the excreted fraction was about 20%. It should be noted that the method used for the measurement of excreted metabolites detects only the more stable fraction of these metabolites that are still present after 1 hr of incubation. Because of this it is likely that the actual amount of such excreted metabolites was (much) higher. The calculated excreted fraction must therefore be considered as the lower limit of the actual excreted fraction. Since the intracellular GSH depletions for CP were at least as high as those for 3-HAA, and since the excretion seemed to be somewhat lower for CP, the excreted fraction of CP metabolites is probably also lower. This led us to the use of 3-HAA in the co-incubations of hepatocytes and erythrocytes. For technical reasons enforced by the geometry of the 'transwells', the dilution of excreted metabolites was even higher in these coincubations (incubation volume 4.1 ml instead of 1.5 ml), leading to a calculated 3-HAA metabolite concentration of 3.7 μ M outside the erythrocytes at the end of the incubation. Even if we suppose that all of this substance enters the erythrocytes during the experiment, erythrocyte GT depletion would have been only 5% and therefore not detectable. As explained above, the actual metabolite concentration during the experiments may have been higher than that detected at the end of the hepatocyte incubations. If we assume, for instance, that the actual metabolite concentration was about 40 μ M (i.e. 10 times higher than that actually detected), the necessary permeability coefficient (*P*) for unidirectional diffusion can be calculated from $P = [V/(A \times \Delta c)]dc/dt$ (Rubinow, 1975). Where the volume of erythrocytes in the incubation (*V*) is 200 μ l, the surface area of those erythrocytes (*A*) is 0.36 m² (see above), the calculated concentration gradient over the cell membranes is 40 μ M and the change of the intracellular erythrocyte concentration (*dc/dt*) must be at least 10% of the GSH concentration (10% of 1.5 mM) in 1 hr. This

means that P must be at least 5.8×10^{-8} cm/sec. For comparison, known values are about 10^{-7} cm/sec for glucose and 10^{-10} cm/sec and lower for ions (Alberts *et al.*, 1983). This indicates that even with this 10-fold higher excretion, effective depletion would have been detectable within 1 hr only when the diffusion uptake speed of the metabolites was at least 60% of the uptake speed of glucose. The two most important factors limiting erythrocyte GSH depletion are therefore (a) the total erythrocyte concentration (higher amounts of erythrocytes leading to higher amounts of GSH that are more difficult to deplete in substantial amounts) and (b) total incubation volume (higher volumes leading to dilution of metabolites and thereby to a lower metabolite gradient over the membrane and thus to lower diffusion speed).

To increase the excretion of GSH-reactive metabolites by the hepatocytes, hepatocytes were preincubated with diethyl maleate in order to deplete their glutathione store. Whereas this treatment led to over 70% depletion of GT in the hepatocytes, no effect of this treatment on erythrocyte GT was found. Since sulfation by isolated hepatocytes can be reduced extensively when no inorganic sulfate is available (Evelo *et al.*, 1984), this treatment may increase the amount of unconjugated reactive metabolites in the hepatocytes and, in case of excretion, in the supernatant. However, isolation of hepatocytes with sulfate-free buffer solutions, and incubation of hepatocytes and erythrocytes in sulfate-free Krebs buffer, did not deplete erythrocyte GT when 3-HAA was tested. Addition of β -glucuronidase/arylsulfatase to incubations composed of GSH and supernatant that was previously incubated with hepatocytes and 3-HAA, also had no effect on GT depletions.

In summary, the direct GSH-reactive compounds IACa, NEM and DEM were able to enter the erythrocyte and deplete the erythrocyte GSH store. CP, 3-HAA and 2-MF depleted erythrocyte GT only when MAS was added, indicating that GSH-reactive metabolites were formed that were able to enter the erythrocyte. Hepatocytes also metabolized 3-HAA and CP into GSH-reactive metabolites. They were able to excrete a fraction of these GSH-reactive metabolites into the supernatant. For 3-HAA, no erythrocyte GT depletion was found in co-incubations of hepatocytes and erythrocytes, which may be explained by uptake limitation of the GSH-reactive metabolites into the erythrocytes.

Acknowledgements—We wish to thank Professor Dr P. Th. Henderson for critical reading of the manuscript, Dr A. Kester for his advice on the statistical analyses and the Red Cross Blood Bank 'Zuid Limburg' for collecting the blood samples.

REFERENCES

- Alberts B., Bray D., Lewis J., Raff M., Roberts K. and Watson J. D. (1983) *Molecular Biology of the Cell*. p. 287. Garland, New York.
- Anderson M. E. (1985) Determination of glutathione and glutathione disulfide in biological samples. *Methods in Enzymology* **113**, 548–555.
- Belvedere G. and Tursi F. (1981) Styrene oxidation to styrene oxide in human blood erythrocytes and lymphocytes. *Research Communications in Chemical Pathology and Pharmacology* **33**, 273–282.
- Berry M. N. and Friend D. S. (1969) High yield preparation of isolated rat liver parenchymal cells. *Journal of Cell Biology* **43**, 506–520.
- Calabrese E. J., Tilli F., Horton H. M. and Stoddard A. (1988) The effects of ethanol on the hematotoxicity of twelve pharmaceutical and environmental agents. *Journal of Environmental Science and Health A23*, 359–367.
- DeLeve L. D. and Kaplowitz N. (1991) Glutathione metabolism and its role in hepatotoxicity. *Pharmacology and Therapeutics* **52**, 287–305.
- Duverger-van Bogaert M., Crutzen-Fayt M. C. and Stecca C. (1991) Mutagenicity of some heterocyclic amines in *Salmonella typhimurium* with metabolic activation by human red blood cell cytosol. *Mutation Research* **261**, 261–265.
- Evelo C. T. A. and Henderson P. Th. (1988) Influence of glutathione on the formation of cysteine alkylation products in human hemoglobin. *Toxicology* **52**, 177–186.
- Evelo C. T. A. and Henderson P. Th. (1992) Biological effect monitoring. *Archives of Toxicology* (Suppl. 15), 268–277.
- Evelo C. T. A., Versteegh J. F. M. and Blaauboer B. J. (1984) Kinetics of the formation and secretion of the aniline metabolite 4-aminophenol and its conjugates by isolated rat hepatocytes. *Xenobiotica* **14**, 409–416.
- Fazi A., Mancini U., Piatti E., Accorsi A. and Magnani M. (1991) Human red blood cells as bioreactors for the inactivation of harmful xenobiotics. *Biotechnology and Applied Biochemistry* **14**, 60–68.
- Garle M. J. and Fry J. R. (1989) Detection of reactive metabolites in vitro. *Toxicology* **54**, 101–110.
- Garle M. J. and Fry J. R. (1990) Reactive metabolite formation catalysed by cytochrome P-450j. *Toxicology in Vitro* **4**, 493–496.
- Garle M. J., Khan J. and Fry J. R. (1988) Depletion of glutathione by the hepatotoxins paracetamol and bromobenzene, and their non-hepatotoxic analogues, in a fortified liver microsomal system. *Toxicology in Vitro* **2**, 247–252.
- Guengerich F. P. and Liebler D. C. (1985) Enzymatic activation of chemicals to toxic metabolites. *Critical Reviews in Toxicology* **14**, 259–307.
- Guyton A. C. (1986) *Textbook of Medical Physiology*. 7th Ed. p. 42. W. B. Saunders, Philadelphia.
- Jauregui H. O., Hayner N. T., Driscoll J. L., Williams-Holland R., Lipsky M. H. and Galletti P. M. (1981) Trypan blue dye uptake and lactate dehydrogenase in adult rat hepatocytes—freshly isolated cells, cell suspensions, and primary monolayer cultures. *In Vitro Cellular and Developmental Biology* **17**, 1100–1110.
- Lo Jacono F., Stecca C. and Duverger M. (1992) Mutagenic activation of benzo[a]pyrene by human red blood cells. *Mutation Research* **268**, 21–26.
- Lowry O. H., Rosebrough N. J., Farr A. L. and Randall R. J. (1951) Protein measurement with the Folin phenol reagent. *Journal of Biological Chemistry* **193**, 265–275.
- Mannervik B. and Danielson U. H. (1988) Glutathione transferases: structure and catalytic activity. *Critical Reviews in Biochemistry* **23**, 283–337.
- Meister A. and Anderson M. E. (1983) Glutathione. *Annual Review of Biochemistry* **52**, 711–760.
- Mieyal J. J., Ackerman R. S., Blumer J. L. and Freeman L. S. (1976) Characterization of enzyme-like activity of human hemoglobin: properties of the haemoglobin-P-450 reductase-coupled aniline hydroxylase system. *Journal of Biological Chemistry* **251**, 3436–3441.

- Moss D. W., Henderson A. R. and Kachmar J. F. (1986) Enzymes. In *Textbook of Clinical Chemistry*. Edited by N. W. Tietz. p. 1532. W. B. Saunders, Philadelphia.
- Mulders T. M. T. (1995) *In vivo* characterization of glutathione conjugation in humans. PhD thesis, Leiden University.
- Norppa H., Vainio H. and Sorsa M. (1983) Metabolic activation of styrene by erythrocytes detected as increased sister chromatid exchanges in cultured human lymphocytes. *Cancer Research* **43**, 3579–3582.
- Palmen N. G. M. and Evelo C. T. A. (1993) Glutathione depletion in human erythrocytes as an indicator for microsomal activation of cyclophosphamide and 3-hydroxyacetanilide. *Toxicology* **84**, 157–170.
- Rashed M. S., Myers T. G. and Nelson S. D. (1990) Hepatic protein arylation, glutathione depletion, and metabolite profiles of acetaminophen and a non-hepatotoxic regioisomer, 3'-hydroxyacetanilide, in the mouse. *Drug Metabolism and Disposition* **18**, 765–770.
- Rubinow S. I. (1975) *Introduction to Mathematical Biology*. Wiley & Sons, New York.
- Sabbioni G. and Neumann H. G. (1990) Biomonitoring of arylamines: hemoglobin adducts of urea and carbamate pesticides. *Carcinogenesis* **11**, 111–115.
- Seglen P. O. (1973) Preparation of rat liver cells. *Experimental Cell Research* **82**, 391–398.
- Stecca C. and Duverger-van Bogaert M. (1989) *N*-Demethylation reactions in intact erythrocytes and erythrocyte supernatant. *Archives of Toxicology* (Suppl. 13), 291–293.
- Strange R. C., Johnson P. H., Lawton A., Moulton J. A., Tector M. J., Tyminski R. J. and Cotton W. (1982) Studies on the variability of glutathione *S*-transferase from human erythrocytes. *Clinica Chimica Acta* **120**, 251–260.
- Tingle M. D. and Park B. K. (1993) The use of a three compartment *in vitro* model to investigate the role of hepatic metabolism in drug-induced blood dyscrasias. *British Journal of Clinical Pharmacology* **36**, 31–38.
- Tursi F., Samaia M., Salmons M. and Belvedere G. (1983) Styrene oxidation to styrene oxide in human erythrocytes is catalyzed by oxyhemoglobin. *Experientia* **39**, 593–594.
- van Kampen E. J. and Zijlstra W. G. (1965) Determination of hemoglobin and its derivatives. *Advances in Clinical Chemistry* **8**, 141–187.